Credit: Getty Images Drugs for diabetic kidney disease treatment have greatly expanded ... Overcoming Therapeutic Inertia Despite advances in drug therapy, patient outcomes have not improved ...

The cystatin C assay market is set for significant expansion as the global healthcare landscape shifts toward early detection ...

Nov 2024 - PYC Therapeutics (ASX:PYC) has announced plans to advance its investigational drug candidate, PYC-003, into human ...

The risk for emergently treated hypocalcemia in individuals receiving denosumab peaked at 2 weeks after administration and ...

But despite progress in developing innovative treatments and revisions to international treatment guidelines 1 for CKD in diabetes, patients have often not received the recommended standard of care 3.

Purpose The evidence evaluating the efficacy of i.v. versus oral iron for the treatment of iron deficiency in non-hemodialysis-dependent patients with chronic kidney disease (CKD) is reviewed.

Otsuka Holdings Co (JP:4578) has released an update. Otsuka Holdings Co. has reported positive interim results from their Phase 3 trial of sibeprenlimab, a promising treatment for immunoglobulin A ...

Otsuka Holdings Co. has reported positive interim results from their Phase 3 trial of sibeprenlimab, a promising treatment for immunoglobulin A nephropathy in adults. The trial demonstrated a ...

which was indeed higher in patients with CKD? A smaller, more detailed study of physician behaviors during ACS hospitalizations and at discharge might help delineate the basis for these treatment ...